"It was wide open a minute ago." Who’s lining up next? It’s become quite the parlor game, now that the biotech IPO window has b...

The federal government may be on the verge of a shutdown, with ‘unprecedented implications’ for new drug reviews, as our friends at ...

On the face of it, GlaxoSmithKline PLC’s deal with the non-profit Community Care of North Carolina to improve medication management seem...

With all the noise this year about IPOs in our little corner of the world, it’s been easy to forget that most biotechs out there are scra...

Over the last month China pharma issues have been on the front page as the government has launched a wide-ranging probe focused on complia...

We live in strange times. Venture capitalists, the traditional support for research-stage biopharmas, have been pulling back from early ...

If the rest of the year is like spring and summer, we are in for one of the busiest years ever for biotech IPOs . With four more slated...

Parkinson’s disease is about to receive plenty of media attention. Most of that will come as NBC’s The Michael J. Fox Show makes its deb...